Breast cancer is the leading type of cancer in terms of number of cases and rapid increase in the number of newly diagnosed breast cancer is observed during the past few years.
Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975
Breast cancer is the leading type of cancer in terms of number of cases and rapid increase in the number of newly diagnosed breast cancer is observed during the past few years. Besides the availability of various breast cancer targeting therapeutic agents, the mortality rate is increasing at an alarming rate and hence there is an immediate need of ideal therapeutic candidate for improving the survival rate of breast cancer. Therapeutic antibodies are emerging as an ideal therapeutic class for the management of breast cancer, which is able to target the breast cancer with higher effectively and fewer side effects.
Over the past few years, the drugs of breast cancer antibody drug class have reached the best-selling drugs in the cancer therapeutics industry, making the class achieve world class recognition when compared with the other viable and commercial drugs of chemotherapy and radiation therapy. One of the major reasons responsible for the rapid growth of breast cancer antibody market is related to their utilization as first line treatment, second line treatment and their ability to target breast cancer as combinational therapy. Along with this, the antibodies can also be used in neoadjuvant and adjuvant therapy while their compatibility with the various chemotherapeutic drugs makes them an ideal candidate for improving the survival rate of breast cancer’s patients. Moreover, high specificity and less associated side effects are also enhancing their uptake among breast cancer patients.
Further, to improve the efficacy of chemotherapeutic drugs and monoclonal antibodies, an advanced class of drugs is recently developed, which is termed as antibody drug conjugates and elevation in therapeutic efficacy is observed by using this advanced approach. Antibody drug conjugates (ADC) are combination of monoclonal antibodies and cytotoxic drugs, which are conjugated with the help of a linker. In ADCs, the monoclonal antibody provides targeted delivery of cytotoxic drug, which results in the destruction of cancerous cells and tumors. This combination improves the therapeutic index of cytotoxic drugs and reduces their cytotoxic profile and intense research work related to this class is under observation. Till date, a cocktail of antibody drug conjugates have entered the market for the management of breast cancer.
Among all therapeutic breast cancer antibodies, human epidermal growth factor receptor (Her2) targeting antibodies are most commonly used which is mainly due to the high expression of HER2 in breast cancer patients. Further, various biosimilars of breast cancer targeting antibodies have also available in the market which have shown high adoption rates in the market. The biosimilar acts as an ideal cheaper variant, which has the ability to reduce the overall cost of treatment and hence are more preferred over branded counterparts. Currently, the share of biosimilar in the breast cancer monoclonal antibodies market is small but it is expected to lead the breast cancer antibodies market in future as the growth in this sector is occurring at exponential rate.
As per our report findings, the global breast cancer antibody market is expected to surpass US$ 15 Billion by 2028 which is mainly due to surge in prevalence of breast cancer and high demand of targeted drugs. Our report provides comprehensive analysis on the commercially available breast cancer antibodies in the global market and insights into their patents, pricing, dosage, and sales. In addition, the report also provides in-depth analysis on the ongoing clinical trials in the market and key drugs in research and development. The report also houses a large number of companies which are competing in this sector. The key players mentioned in the report include Merck, Pfizer, Roche, Amgen, Zydus Cadila, Gilead Science, Samsung Bio, and Marcogenics.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366